The expanding clinical indications for SGLT2 inhibitors hold promise for a broader range of patients beyond those with diabetes: SGLT2 inhibitors have already received approval for heart failure management in patients with or without diabetes. This evidence concerns the gene SLC5A2 and diabetes mellitus.